Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Medullary × pralsetinib × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Thoracic Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Neoplasms, Nerve Tissue 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Lung Neoplasms 1 Lung Diseases 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Medullary 1 Carcinoma, Bronchogenic 1 Carcinoma 1 Bronchial Diseases 1 Adenocarcinoma 1

Interventions

vandetanib 4 cabozantinib 2 selpercatinib 1 pralsetinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04760288 2024-01-05

AcceleRET-MTC

Hoffmann-La Roche

Phase 3 Withdrawn

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡